Mersana Therapeutics stock opened at $0.48 on Monday. The firm has a market cap of $59.30 million, a price-to-earnings ratio of -0.79 and a beta of 1.39. Mersana Therapeutics has a 1 year low of ...

Martin Huber; President, Chief Executive Officer, Director; Mersana Therapeutics Inc Brian ... 2056 is our immunosynthen STING agonist ADC targeting a novel epitope of HER2. Later in 2025, we ...

Revenue: US$40.5m (up 9.9% from FY 2023). Net loss: US$69.2m (loss narrowed by 60% from FY 2023). US$0.56 loss per share (improved from US$1.48 loss in FY 2023). Revenue exceeded analyst estimates ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) – Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D.

Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...

Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...

Mersana Therapeutics, Inc., a pharmaceutical company based in Cambridge, Massachusetts, has received a notification from The Nasdaq Stock Market LLC regarding non-compliance with the exchange's ...

Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...

Sting, the legendary frontman of The Police and a massively successful solo artist, has carved out one of the most diverse and enduring careers in modern music. With a blend of rock, jazz ...